|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
UNIPROT |
Our results indicate that mutations of the tyrosine kinase domain of the MET gene may be involved in the acceleration of the carcinogenesis in childhood HCC.
|
9927037 |
1999 |
|
Liver carcinoma
|
1.000 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Papillary Renal Cell Carcinoma
|
0.800 |
SomaticCausalMutation
|
disease |
ORPHANET |
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
|
26536169 |
2016 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CTD_human |
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
|
25401301 |
2015 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
|
18055465 |
2008 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
The MET oncogene drives a genetic programme linking cancer to haemostasis.
|
15772665 |
2005 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele.
|
15557554 |
2004 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.
|
10433944 |
1999 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
|
9140397 |
1997 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
Activating mutations for the met tyrosine kinase receptor in human cancer.
|
9326629 |
1997 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors.
|
1917129 |
1991 |
|
Papillary Renal Cell Carcinoma
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
CTD_human |
Crizotinib thus shows a marked antitumor action both in vitro and in vivo specifically in gastric cancer cells positive for MET amplification.
|
22729845 |
2012 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
CTD_human |
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
22042947 |
2011 |
|
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of stomach
|
0.700 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
|
25401301 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
|
24688052 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS.
|
22787409 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
MET is overexpressed in 61% of NSCLC cases.
|
21815704 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
21623265 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Stomach Neoplasms
|
0.580 |
Biomarker
|
group |
CTD_human |
Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
|
22729845 |
2012 |